gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AVRHealthcareOrthopedic & Surgical Supplies

Anteris Technologies Global Corp. Common Stock (AVR)

$6.12+9.29%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$5.60▲ 28.74% in range
Nov 3, 2025Low $3.38 · High $10.57Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Anteris Technologies Global closed at $6.12 on Nov 4, up 9.29%, 42.1% below its 52-week closing high. Volume of 1.2M shares was 0.69× its 20-day average (below normal).

Split-adjusted performance: -13.2% over one month, -4.2% over six months, +40.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.01M, up 63.3% from a year earlier, with a net margin of -2883.4%.

Short interest was 7.9M shares at the Oct 15 settlement, up 18.9% from the prior report (9.6% of float, 5.0 days to cover).

Market cap$596.4M97.5M shares
Revenue · quarter$1.0M+63.3% YoY
Diluted EPS$-0.30—
P/E · TTM—P/S 266.0×
Net margin-2,883.4%Gross 76.9%
Dividend yieldNone
52-week range3.38 – 10.57−42.1% from high
Volume1.2M0.69× 20-day avg
Volatility · 60d50.7%Annualised
Short % of float9.6%5.0 days to cover
Net cash$256.9MCash $257.4M
Next earnings—Not scheduled
Split-adjusted performance
1W +0.3%1M −13.2%3M −26.8%6M −4.2%YTD +22.6%1Y +40.7%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Orthopedic & Surgical Supplies

Percentile among 22 companies (100 = best)

6-month momentum35
Revenue growth95
Net margin5
Value (low P/E)—
Size57

Industry medians: 6-month return +1.5%, revenue growth +12.8%, net margin −2.8%, P/E 29.2×.

Short interest

Details →
Shares short7.9M+18.9% vs prior
Days to cover5.0Settled Oct 15
% of float9.6%
Short vol. 10d56.6%of daily volume

Closest peers by size in Orthopedic & Surgical Supplies

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AVRAnteris Technologies Global$6.12+9.29%−4.2%+63.3%−2883.4%—$596.4M
SMTISanara MedTech$32.33+0.50%+68.8%+9.0%−1.6%—$297.0MCompare
CDRECadre Holdings$30.84−0.71%0.0%+31.8%5.5%36.6$1.32BCompare
ENOVEnovis$24.42+16.90%−1.7%+3.2%−0.2%—$1.41BCompare
INGNInogen$7.22+2.85%+1.5%+3.0%−4.0%—$191.6MCompare
ESTAEstablishment Labs Holdings$66.94+9.02%−10.2%+31.7%−17.4%—$1.99BCompare
LAKELakeland Industries$8.93−0.11%−7.3%−4.5%−9.8%—$88.7MCompare
NTRBNutriband$6.08−3.34%+53.1%−29.7%−201.3%—$73.9MCompare
CNXUConexeu Sciences$2.22−6.72%————$68.4MCompare

News about Anteris Technologies Global

All news →
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026GlobeNewswire Inc. · 3d ago▲ PositiveAnteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026GlobeNewswire Inc. · Oct 27, 2026▲ PositiveAnteris Advances Global PARADIGM Trial Expansion with German Regulatory ClearanceGlobeNewswire Inc. · Oct 20, 2026▲ PositiveAnteris to Present at September Healthcare Investor ConferencesGlobeNewswire Inc. · Aug 31, 2026▲ PositiveAnteris Advances Global PARADIGM Expansion with French Regulatory ClearanceGlobeNewswire Inc. · Jun 8, 2026▲ Positive

Quick answers

What does Anteris Technologies Global do?
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve.
What is AVR's market cap?
$596.45M, based on the Nov 4 close of $6.12.
Does Anteris Technologies Global pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AVR is sold short?
7.9M shares, 9.6% of float, as of Oct 15, 2026.
What sector is AVR in?
Healthcare, in the Orthopedic & Surgical Supplies industry.

About Anteris Technologies Global

Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.

HQ: Eagan, MN174 employeesListed Dec 13, 2024anteristech.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology